drugset
drugset / Trial / NCT03737448

TRimetazidine for acUte on Chronic Liver Failure STudy

NCT03737448 ↗

Phase 1 Suspended 30 enrolled Martin Pharmaceuticals
Non-randomizedSequentialOpen-labelOther

Summary

The study will assess the pharmacokinetics (PK), tolerability, and safety of oral trimetazidine administered to subjects with AD (ACLF Grade 0) or with ACLF Grade 1 or 2.

Timeline

Start
2018-11-28
Primary completion
2021-06-30
Completion
2021-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Trimetazidine Small molecule 60 mg Oral

Indications

liver disorder